JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
Allist Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
University of Chicago
M.D. Anderson Cancer Center
Laval University
National Institutes of Health Clinical Center (CC)
Cybrexa Therapeutics
Mercy Medical Center
Revolution Medicines, Inc.
Dublin City University